Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

rocket pharmaceuticals inc. - RCKT

RCKT

Close Chg Chg %
3.86 -0.15 -3.89%

Closed Market

3.71

-0.15 (3.89%)

Volume: 754.69K

Last Updated:

Sep 8, 2026, 4:00 PM EDT

Trade Now

Company Overview: rocket pharmaceuticals inc. - RCKT

RCKT Key Data

Open

$3.78

 Day Range

3.68 - 3.78

52 Week Range

2.53 - 5.45

 Market Cap

$423.73M

Shares Outstanding

109.78M

 Public Float

103.55M

Beta

0.50

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.16

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.32M

  

RCKT Performance

1 Week
 
 0.00%
 
1 Month
 
 6.93%
 
3 Months
 
 40.36%
 
1 Year
 
 22.15%
 
5 Years
 
 -89.07%
 

RCKT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 15
Full Ratings ➔

About rocket pharmaceuticals inc. - RCKT

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The firm's multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

RCKT At a Glance

Rocket Pharmaceuticals, Inc.
9 Cedarbrook Drive
Cranbury, New Jersey 08512
Phone 1-609-659-8001 Revenue 0.00
Industry Biotechnology Net Income -223,123,000.00
Sector Health Technology Employees 202
Fiscal Year-end 12 / 2026
View SEC Filings

RCKT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 1.371
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.039
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.11

RCKT Efficiency

Revenue/Employee N/A
Income Per Employee -1,104,569.307
Receivables Turnover N/A
Total Asset Turnover N/A

RCKT Liquidity

Current Ratio 6.381
Quick Ratio 6.381
Cash Ratio 6.255

RCKT Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -52.001
Return on Equity -60.266
Return on Total Capital -73.858
Return on Invested Capital -56.842

RCKT Capital Structure

Total Debt to Total Equity 8.974
Total Debt to Total Capital 8.235
Total Debt to Total Assets 7.528
Long-Term Debt to Equity 7.922
Long-Term Debt to Total Capital 7.27
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Rocket Pharmaceuticals Inc. - RCKT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
6.27M 7.10M 9.38M 11.03M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
6.27M 7.10M 9.38M 11.03M
Depreciation
6.27M 7.10M 9.38M 11.03M
Amortization of Intangibles
- - - -
-
COGS Growth
+16.62% +13.28% +32.08% +17.60%
Gross Income
(6.27M) (7.10M) (9.38M) (11.03M)
Gross Income Growth
-16.62% -13.28% -32.08% -17.60%
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
218.08M 252.56M 263.83M 217.49M
Research & Development
161.53M 180.97M 165.22M 135.71M
Other SG&A
56.54M 71.59M 98.61M 81.78M
SGA Growth
+34.64% +15.81% +4.46% -17.56%
Other Operating Expense
- - - -
-
Unusual Expense
- - 1.88M 3.33M
-
EBIT after Unusual Expense
(224.34M) (259.66M) (275.08M) (231.85M)
Non Operating Income/Expense
3.84M 15.94M 18.22M 10.62M
Non-Operating Interest Income
3.84M 15.94M 18.22M 10.62M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.86M 1.88M 1.89M 1.89M
Interest Expense Growth
-37.45% +0.70% +0.59% +0.27%
Gross Interest Expense
1.86M 1.88M 1.89M 1.89M
Interest Capitalized
- - - -
-
Pretax Income
(222.36M) (245.59M) (258.75M) (223.12M)
Pretax Income Growth
-30.75% -10.45% -5.35% +13.77%
Pretax Margin
- - - -
-
Income Tax
- - - (500.00K)
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - 500.00K
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(221.86M) (245.59M) (258.75M) (223.12M)
Minority Interest Expense
- - - -
-
Net Income
(221.86M) (245.59M) (258.75M) (223.12M)
Net Income Growth
-31.23% -10.70% -5.35% +13.77%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(221.86M) (245.59M) (258.75M) (223.12M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(221.86M) (245.59M) (258.75M) (223.12M)
EPS (Basic)
-3.2556 -2.9234 -2.7292 -2.0079
EPS (Basic) Growth
-21.77% +10.20% +6.64% +26.43%
Basic Shares Outstanding
68.15M 84.01M 94.81M 111.12M
EPS (Diluted)
-3.2556 -2.9234 -2.7292 -2.0079
EPS (Diluted) Growth
-21.77% +10.20% +6.64% +26.43%
Diluted Shares Outstanding
68.15M 84.01M 94.81M 111.12M
EBITDA
(218.08M) (252.56M) (263.83M) (217.49M)
EBITDA Growth
-34.64% -15.81% -4.46% +17.56%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 8.625
Number of Ratings 15 Current Quarters Estimate -0.40
FY Report Date 09 / 2026 Current Year's Estimate -0.13
Last Quarter’s Earnings 1.08 Median PE on CY Estimate N/A
Year Ago Earnings -2.01 Next Fiscal Year Estimate -1.332
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 13 13 12 14
Mean Estimate -0.40 -0.41 -0.13 -1.33
High Estimates -0.30 -0.24 0.08 -0.13
Low Estimate -0.43 -0.55 -0.22 -1.84
Coefficient of Variance -9.35 -16.72 -63.69 -33.54

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 6
OVERWEIGHT 0 0 0
HOLD 7 7 6
UNDERWEIGHT 0 0 0
SELL 2 2 2
MEAN Overweight Overweight Overweight

Insider Actions for Rocket Pharmaceuticals Inc. - RCKT

Date Name Shares Transaction Value
Jul 8, 2026 Carsten Boess Director 64,860 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 8, 2026 Fady Ibraham Malik Director 64,860 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 8, 2026 Fady Ibraham Malik Director 52,862 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 8, 2026 Mikael Dolsten Director 64,860 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 8, 2026 Mikael Dolsten Director 67,082 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 8, 2026 Peter Marc Fong Director 64,860 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 8, 2026 Peter Marc Fong Director 76,195 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 8, 2026 Roderick Tze Ian Wong Director 78,960 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 8, 2026 Roderick Tze Ian Wong Director 75,499 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 8, 2026 David P. Southwell Director 64,860 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 8, 2026 David P. Southwell Director 54,522 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 8, 2026 Carsten Boess Director 52,862 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 21, 2025 John C. Militello See Remarks 65,920 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.98 per share 196,441.60
Nov 21, 2025 Martin L. Wilson General Counsel 383,816 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.98 per share 1,143,771.68
Nov 21, 2025 Gaurav D. Shah CEO; Director 778,296 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.98 per share 2,319,322.08
Nov 21, 2025 Jonathan David Schwartz See Remarks 299,064 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.98 per share 891,210.72
Oct 9, 2025 Syed Rizvi Chief Medical Officer 283,018 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 9, 2025 Syed Rizvi Chief Medical Officer 345,911 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 9, 2025 Syed Rizvi Chief Medical Officer 383,854 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Rocket Pharmaceuticals Inc. in the News